2. Search Result
Search Result
Results for "

rat vas deferens

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

4

Peptides

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1317A
    Nociceptin (1-13), amide TFA

    		Opioid Receptor Neurological Disease
    Nociceptin (1-13), amide TFA is a potent ORL1 receptor (opioid receptor-like 1 receptor, OP4) agonist with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes .
    Nociceptin (1-13), amide TFA
  • HY-P3679
    Neuropeptide Y (1-24) (human)

    		Neuropeptide Y Receptor Neurological Disease
    Neuropeptide Y (1-24) (human) is a neuropeptide with potencies in inhibiting the electricity stimulated twitch response of rat vas deferens. Neuropeptide Y (1-24) (human) stimulates N-methyl-D-aspartate (NMDA)-induced neuronal activation in the rat CA3 region of the dorsal hippocampus in vivo .
    Neuropeptide Y (1-24) (human)
  • HY-P1317
    Nociceptin (1-13), amide

    		Opioid Receptor Neurological Disease
    Nociceptin (1-13), amide is a potent ORL1 receptor (opioid receptor-like 1 receptor, OP4) agonist with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes .
    Nociceptin (1-13), amide
  • HY-160932
    RS-15385-198

    		Others Endocrinology
    RS-15385-198 is the enantiomer of Delequamine (RS-15385-197) (HY-106874). RS-15385-198 exhibits a pKi of 6.32 for α2-adrenoceptors in the rat cortex. RS-15385-198 is an antagonist for UK-14304 (HY-B0659) in the rat vas deferens and in the guinea-pig ileum .
    RS-15385-198
  • HY-116680
    LY53857

    		5-HT Receptor Cardiovascular Disease Neurological Disease
    LY53857 is a potent antagonist of vasoconstriction and serotonin-mediated 5-HT2 receptors. LY53857 did not reduce mean arterial blood pressure in spontaneously hypertensive rats (SHR) at doses that blocked the depressor response to serotonin and blocked central serotonin receptors. In addition, LY53857 was able to enhance neurotransmitter release in rat vas deferens and guinea pig ileal nerves .
    LY53857
  • HY-108985
    Trazium esilate

    EGYT-3615

    		 Others Neurological Disease
    Trazium esilate (EGYT-3615) is an antidepressant, which influences the central dopaminergic system. Trazium esilate synergizes amphetamine, potentiates stereotypy and hypermotility. Trazium esilate blocks Apomorphine (HY-12723)-induced hypothermic and the stereotypy, and Bulbocapnine (HY-W436270)-induced cataleptic state. Trazium esilate enhances the effect of Norepinephrine (HY-13715) on isolated vas deferens of the rat .
    Trazium esilate
  • HY-110016
    Docosatetraenylethanolamide

    DEA

    		 Endogenous Metabolite Cannabinoid Receptor Neurological Disease
    Docosatetraenylethanolamide (DEA) is a cannabinoid receptor 1 (CB1) agonist. Docosatetraenylethanolamide inhibits the specific binding of cannabinoid probe to rat synaptosomal membranes with a Ki value of 34.4 nM. Docosatetraenylethanolamide can be used in the research of nervous system .
    Docosatetraenylethanolamide
  • HY-167689
    Parethoxycaine hydrochloride

    		Others Neurological Disease
    Parethoxycaine hydrochloride is an anesthetic with nerve conduction blocking activity. Parethoxycaine hydrochloride exhibits non-selective inhibitory effects on responses to various stimulants in rat vas deferens and guinea pig ileum muscles. Parethoxycaine hydrochloride has an enhanced effect on the action of norepinephrine, and its methyl bromide derivative also exhibits the same properties on the action of norepinephrine and potassium ions. Derivatives of parethoxycaine hydrochloride have significant effects on calcium dose-response curves, displaying different tissue and stimulant selectivities. The mechanism of action of Parethoxycaine hydrochloride involves the regulation of calcium transport processes .
    Parethoxycaine hydrochloride
  • HY-136693
    L-654284

    		Others Neurological Disease
    L-654284 is an α2-adrenergic receptor antagonist with significant selectivity. L-654284 competes with the binding of 3H-clonidine and 3H-rauwolscine in vitro and shows Ki values of 0.8 nM and 1.1 nM, respectively. L-654284 can block the protrusion effect of clonidine in isolated vas deferens in rats, with a pA2 value of 9.1. L-654284 exhibits remarkable selectivity for α2 and α1 adrenergic receptors, and exhibits a Ki of 110 nM in inhibiting 3H-prazosin binding. L-654284 can significantly increase the turnover rate of norepinephrine in rat cerebral cortex in vivo, showing α2-adrenergic receptor blocking activity in the central nervous system .
    L-654284

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: